O	0	3	Met	Met	NN	B-NP
O	4	17	amplification	amplification	NN	I-NP
O	18	21	and	and	CC	O
B-Cancer	22	27	tumor	tumor	NN	B-NP
O	28	39	progression	progression	NN	I-NP
O	40	42	in	in	IN	B-PP
B-Cell	43	49	Cdkn2a	Cdkn2a	NN	B-NP
I-Cell	49	50	-	-	HYPH	B-NP
I-Cell	50	59	deficient	deficient	JJ	I-NP
I-Cell	60	71	melanocytes	melanocyte	NNS	I-NP
O	71	72	.	.	.	O

O	74	79	While	While	IN	B-SBAR
O	80	84	many	many	JJ	B-NP
O	85	92	genetic	genetic	JJ	I-NP
O	93	104	alterations	alteration	NNS	I-NP
O	105	109	have	have	VBP	B-VP
O	110	114	been	be	VBN	I-VP
O	115	125	identified	identify	VBN	I-VP
O	126	128	in	in	IN	B-PP
B-Cancer	129	137	melanoma	melanoma	NN	B-NP
O	137	138	,	,	,	O
O	139	142	the	the	DT	B-NP
O	143	151	relevant	relevant	JJ	I-NP
O	152	161	molecular	molecular	JJ	I-NP
O	162	168	events	event	NNS	I-NP
O	169	173	that	that	WDT	B-NP
O	174	184	contribute	contribute	VBP	B-VP
O	185	187	to	to	TO	B-PP
O	188	195	disease	disease	NN	B-NP
O	196	207	progression	progression	NN	I-NP
O	208	211	are	be	VBP	B-VP
O	212	218	poorly	poorly	RB	I-VP
O	219	229	understood	understand	VBN	I-VP
O	229	230	.	.	.	O

O	231	235	Most	Most	RBS	B-NP
B-Cancer	236	243	primary	primary	JJ	I-NP
I-Cancer	244	249	human	human	JJ	I-NP
I-Cancer	250	259	melanomas	melanoma	NNS	I-NP
O	260	267	exhibit	exhibit	VBP	B-VP
O	268	272	loss	loss	NN	B-NP
O	273	275	of	of	IN	B-PP
O	276	286	expression	expression	NN	B-NP
O	287	289	of	of	IN	B-PP
O	290	293	the	the	DT	B-NP
O	294	300	CDKN2A	CDKN2A	NN	I-NP
O	301	306	locus	locus	NN	I-NP
O	307	309	in	in	IN	B-PP
O	310	318	addition	addition	NN	B-NP
O	319	321	to	to	TO	B-PP
O	322	332	activation	activation	NN	B-NP
O	333	335	of	of	IN	B-PP
O	336	339	the	the	DT	B-NP
O	340	349	canonical	canonical	JJ	I-NP
O	350	357	mitogen	mitogen	NN	I-NP
O	357	358	-	-	HYPH	B-VP
O	358	367	activated	activate	VBN	B-NP
O	368	375	protein	protein	NN	I-NP
O	376	382	kinase	kinase	NN	I-NP
O	383	392	signaling	signaling	NN	I-NP
O	393	400	pathway	pathway	NN	I-NP
O	400	401	.	.	.	O

O	402	404	In	In	IN	B-PP
O	405	409	this	this	DT	B-NP
O	410	415	study	study	NN	I-NP
O	415	416	,	,	,	O
O	417	419	we	we	PRP	B-NP
O	420	424	used	use	VBD	B-VP
O	425	426	a	a	DT	B-NP
O	427	433	Cdkn2a	Cdkn2a	NN	I-NP
O	433	434	-	-	HYPH	B-NP
O	434	443	deficient	deficient	JJ	I-NP
O	444	449	mouse	mouse	NN	I-NP
B-Cell	450	460	melanocyte	melanocyte	NN	I-NP
I-Cell	461	465	cell	cell	NN	I-NP
I-Cell	466	470	line	line	NN	I-NP
O	471	473	to	to	TO	B-VP
O	474	480	screen	screen	VB	I-VP
O	481	484	for	for	IN	B-PP
O	485	494	secondary	secondary	JJ	B-NP
O	495	502	genetic	genetic	JJ	I-NP
O	503	509	events	event	NNS	I-NP
O	510	512	in	in	IN	B-PP
B-Cancer	513	521	melanoma	melanoma	NN	B-NP
I-Cancer	522	527	tumor	tumor	NN	I-NP
O	528	539	progression	progression	NN	I-NP
O	539	540	.	.	.	O

O	541	545	Upon	Upon	IN	B-PP
O	546	559	investigation	investigation	NN	B-NP
O	559	560	,	,	,	O
B-Cellular_component	561	577	intrachromosomal	intrachromosomal	JJ	B-NP
O	578	582	gene	gene	NN	I-NP
O	583	596	amplification	amplification	NN	I-NP
O	597	599	of	of	IN	B-PP
O	600	603	Met	Met	NNP	B-NP
O	603	604	,	,	,	O
O	605	606	a	a	DT	B-NP
O	607	615	receptor	receptor	NN	I-NP
O	616	624	tyrosine	tyrosine	NN	I-NP
O	625	631	kinase	kinase	NN	I-NP
O	632	642	implicated	implicate	VBN	B-VP
O	643	645	in	in	IN	B-PP
B-Cancer	646	654	melanoma	melanoma	NN	B-NP
O	655	666	progression	progression	NN	I-NP
O	666	667	,	,	,	O
O	668	671	was	be	VBD	B-VP
O	672	682	identified	identify	VBN	I-VP
O	683	685	in	in	IN	B-PP
B-Cancer	686	692	Cdkn2a	Cdkn2a	NN	B-NP
I-Cancer	692	693	-	-	HYPH	B-NP
I-Cancer	693	702	deficient	deficient	JJ	I-NP
I-Cancer	703	709	tumors	tumor	NNS	I-NP
O	709	710	.	.	.	O

O	711	714	RNA	RNA	NN	B-NP
O	715	727	interference	interference	NN	I-NP
O	728	737	targeting	target	VBG	B-VP
O	738	741	Met	Met	NN	B-NP
O	742	744	in	in	IN	B-PP
O	745	750	these	these	DT	B-NP
B-Cell	751	756	tumor	tumor	NN	I-NP
I-Cell	757	762	cells	cell	NNS	I-NP
O	763	771	resulted	result	VBD	B-VP
O	772	774	in	in	IN	B-PP
O	775	776	a	a	DT	B-NP
O	777	788	significant	significant	JJ	I-NP
O	789	794	delay	delay	NN	I-NP
O	795	797	in	in	IN	B-PP
B-Cancer	798	803	tumor	tumor	NN	B-NP
O	804	810	growth	growth	NN	I-NP
O	811	813	in	in	FW	B-ADVP
O	814	818	vivo	vivo	FW	I-ADVP
O	819	827	compared	compare	VBN	B-PP
O	828	832	with	with	IN	B-PP
O	833	836	the	the	DT	B-NP
O	837	844	control	control	NN	I-NP
B-Cell	845	850	cells	cell	NNS	I-NP
O	850	851	.	.	.	O

O	852	855	MET	MET	NN	B-NP
O	856	866	expression	expression	NN	I-NP
O	867	869	is	be	VBZ	B-VP
O	870	876	rarely	rarely	RB	I-VP
O	877	885	detected	detect	VBN	I-VP
O	886	888	in	in	IN	B-PP
B-Cancer	889	896	primary	primary	JJ	B-NP
I-Cancer	897	902	human	human	JJ	I-NP
I-Cancer	903	911	melanoma	melanoma	NN	I-NP
O	912	915	but	but	CC	O
O	916	918	is	be	VBZ	B-VP
O	919	929	frequently	frequently	RB	I-VP
O	930	938	observed	observe	VBN	I-VP
O	939	941	in	in	IN	B-PP
B-Cancer	942	952	metastatic	metastatic	JJ	B-NP
I-Cancer	953	960	disease	disease	NN	I-NP
O	960	961	.	.	.	O

O	962	966	This	This	DT	B-NP
O	967	972	study	study	NN	I-NP
O	973	982	validates	validate	VBZ	B-VP
O	983	984	a	a	DT	B-NP
O	985	989	role	role	NN	I-NP
O	990	993	for	for	IN	B-PP
O	994	997	Met	Met	NN	B-NP
O	998	1008	activation	activation	NN	I-NP
O	1009	1011	in	in	IN	B-PP
B-Cancer	1012	1020	melanoma	melanoma	NN	B-NP
I-Cancer	1021	1026	tumor	tumor	NN	I-NP
O	1027	1038	progression	progression	NN	I-NP
O	1039	1041	in	in	IN	B-PP
O	1042	1045	the	the	DT	B-NP
O	1046	1053	context	context	NN	I-NP
O	1054	1056	of	of	IN	B-PP
O	1057	1063	Cdkn2a	Cdkn2a	NN	B-NP
O	1064	1074	deficiency	deficiency	NN	I-NP
O	1074	1075	.	.	.	O

